-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate, also known as FDA-approved drug Lyrica, is used for the treatment of epilepsy, neuropathic pain, and fibromyalgia.
The production process of Lyrica involves several steps, including the synthesis of the starting material, the synthesis of the title compound, and the purification and isolation of the final product.
One of the key steps in the production process of Lyrica is the synthesis of the starting material, 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid.
This compound is synthesized by reacting 2,2-dihydroxyethyl amino oxalate with methyl 4-oxo-1,4-dihydropyridine-2-carboxylate in the presence of a solvent such as acetonitrile or THF.
The reaction is typically carried out at a temperature of 60-70°C and the product is isolated by filtration.
The next step is the synthesis of the title compound, Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate.
This is achieved by reacting the starting material with benzyl bromide in the presence of a catalyst such as cesium carbonate.
The reaction is typically carried out under an inert atmosphere such as nitrogen and the product is isolated by filtration.
The final step in the production process of Lyrica is the purification and isolation of the final product.
This is typically achieved by crystallization, which involves dissolving the crude product in a solvent such as ethyl acetate and then allowing the solvent to evaporate, leaving behind pure crystals of the title compound.
The production process of Lyrica involves several steps, including the synthesis of the starting material, the synthesis of the title compound, and the purification and isolation of the final product.
The starting material is synthesized by reacting 2,2-dihydroxyethyl amino oxalate with methyl 4-oxo-1,4-dihydropyridine-2-carboxylate in the presence of a solvent such as acetonitrile or THF.
The title compound is synthesized by reacting the starting material with benzyl bromide in the presence of a catalyst such as cesium carbonate.
The final product is obtained by crystallization of the crude product in a solvent such as ethyl acetate.
In conclusion, the production process of Lyrica involves several steps, including the synthesis of the starting material, the synthesis of the title compound, and the purification and isolation of the final product.
The starting material is synthesized by reacting 2,2-dihydroxyethyl amino oxalate with methyl 4-oxo-1,4-dihydropyridine-2-carboxylate in the presence of a solvent such as acetonitrile or THF.
The title compound is synthesized by reacting the starting material with benzyl bromide in the presence of a catalyst such as cesium carbonate.
The final product is obtained by crystallization of the crude product in a solvent such as ethyl acetate.
The production process of Lyrica is carried out by a team of skilled chemists and technicians, who ensure that each step is carried out according to the highest standards of quality control.
The purity and potency of the final product are tested using advanced technologies